4Dx Inks Deal with Top US Hospitals

KEY TAKEAWAYS:

• 4Dx, a medical imaging technology start-up, has inked a deal with two of the top hospitals in the United States.
• The deal will allow the conduct of regular trials for the lung-imaging technology of 4Dx while it is waiting for certification from the US FDA.
• 4Dx is eyeing to get additional funding for further research of its technology touted to provide early detection and treatment of lung disease.

Medical technology start-up company, 4Dx, entered into an agreement with UCLA hospitals and the Cleveland Clinic. Majority of its first clinical trial also got financing from Cedars Sinai in Los Angeles. It also eyes to get fresh funding worth $5 million.

The company, which is based in Melbourne, Australia, is a lung imaging company established to pave the way for the commercialisation of the lung imaging technology. This technology deemed significant not only in the early diagnosis of lung disease but also in the effective treatment of such disease.

Current techniques in lung imaging provide a picture of the amount of air taken in by the lungs. However, the technology of 4DX highlights the specific parts of the lungs that are not receiving enough air and thus help in early lung diseases diagnosis.

“We’ve never felt this positive. The feedback is really strong, and no one questions our price. In my mind, we’re undervalued. The Series B will close before Christmas, and the pre-IPO round could potentially be raised just from existing shareholders. We also expect to start generating revenue next year too,” 4DX Chief Executive Andreas Fouras said.

Fouras said the company was able to raise over 50% in its Series B round. This is expected to help finance the business until fresh funds come in through the pre-initial public offering.

The lung imaging technology was discovered and developed by Fouras and his research group at the Monash University. The company has successfully studied and patented the technology for 10 years and this has enabled the company to raise millions of dollars in research funds.

Among the agencies that have contributed funding for 4DX are the American Asthma Foundation and the National Health & Medical Research Council of Australia.
The company is eyeing a $16.3 billion market in the United States but it has to position its technology as the leading technology for lung imaging before it can get into that market. The deal with the top two hospitals in the United States is expected to contribute to this goal.

It is also banking on getting the US Food and Drug Administration clearance to establish is credibility. Until such time, 4DX could not promote its technology, and it will just have to rely on its hospital partners for the conduct of the regular trials.

About 4Dx

4Dx brings a technological solution set to disrupt this multi-billion dollar sector through compelling unique competitive advantages over existing respiratory diagnostics. The respiratory diagnostic sector represents a global market of over $25B per annum. Currently served by out of date technology, 4Dx has enormous scope for financial success as well as life-changing advancement for medicine. Offering more detailed information, faster validation of treatment efficacy, lower costs, and reduced radiation dosage, 4Dx allows for earlier detection of disease and earlier intervention.The ability to identify lung diseases earlier is creating a critical shift in the practice model from cure to prevention.

Request Offer